FILE TYPE

Found 5 results.

Jan, 16 2025 (v1) - Journal article (Open Access)

A European network to develop virtual twin technology for personalized stroke management in atrial fibrillation: the TARGET consortium

Ortega-Martorell, Sandra; Olier, Ivan; Lip, Gregory; TARGET consortium

Uploaded on Mar, 27 2025

Atrial fibrillation (AF) is a prevalent heart arrhythmia that increases stroke risk, leading to severe complications, high costs, and poor recovery outcomes. To address this, the European Union’s Horizon Europe research programme has funded the TARGET project to develop personalized stroke management strategies for AF-related stroke (AFRS) patients. To achieve this, TARGET will capitalize on the power of artificial intelligence (AI), virtual twin technologies, and in silico trials and will further advance the work in the direction of the personalization of care.

Nov, 07 2024 (v1) - Journal article (Open Access)

TARGET: A Major European Project Aiming to Advance the Personalised Management of Atrial FibrillationRelated Stroke via the Development of Health Virtual Twins Technology and Artificial Intelligence

Ortega-Martorell, Sandra; Olier, Ivan; Lip, Gregory; Ohlsson, Mattias; TARGET consortium

Uploaded on Mar, 27 2025

Dec, 07 2024 (v1) - Journal article (Open Access)

Advancing personalised care in atrial fibrillation and stroke: The potential impact of AI from prevention to rehabilitation

Ortega-Martorell, Sandra; Olier, Ivan; Lip, Gregory; Ohlsson, Mattias; TARGET consortium

Uploaded on Mar, 27 2025

Atrial fibrillation (AF) is a complex condition caused by various underlying pathophysiological disorders and is the most common heart arrhythmia worldwide, affecting 2 % of the European population. This prevalence increases with age, imposing significant financial, economic, and human burdens. In Europe, stroke is the second leading cause of death and the primary cause of disability, with numbers expected to rise due to ageing and improved survival rates. Functional recovery from AF-related stroke is often unsatisfactory, leading to prolonged hospital stays, severe disability, and high mortality.
Despite advances in AF and stroke research, the full pathophysiological and management issues between AF and stroke increasingly need innovative approaches such as artificial intelligence (AI) and machine learning (ML). Current risk assessment tools focus on static risk factors, neglecting the dynamic nature of risk influenced by acute illness, ageing, and comorbidities. Incorporating biomarkers and automated ECG analysis could enhance pathophysiological understanding.
This paper highlights the need for personalised, integrative approaches in AF and stroke management, emphasising the potential of AI and ML to improve risk prediction, treatment personalisation, and rehabilitation outcomes. Further research is essential to optimise care and reduce the burden of AF and stroke on patients and healthcare systems.

Aug, 16 2024 (v1) - Journal article (Open Access)

AI-based derivation of atrial fibrillation phenotypes in the general and critical care populations

Bellfield, Ryan A. A.; Lotto, Robyn; Olier, Ivan; Jones, Ian; Dawnson, Ellen A.; Guowei, Li; Tuladhar, Anil M.; Lip, Gregory; Ortega-Martorell, Sandra

Uploaded on Mar, 27 2025

Background Atrial fibrillation (AF) is the most common heart arrhythmia worldwide and is linked to a higher risk of mortality and morbidity. To predict AF and AF-related complications, clinical risk scores are commonly employed, but their predictive accuracy is generally limited, given the inherent complexity and heterogeneity of patients with AF. By classifying different presentations of AF into coherent and manageable clinical phenotypes, the development of tailored prevention and treatment strategies can be facilitated. In this study, we propose an artificial intelligence (AI)-based methodology to derive meaningful clinical phenotypes of AF in the general and critical care populations.

Methods Our approach employs generative topographic mapping, a probabilistic machine learning method, to identify micro-clusters of patients with similar characteristics. It then identifies macro-cluster regions (clinical phenotypes) in the latent space using Ward’s minimum variance method. We applied it to two large cohort databases (UK-Biobank and MIMIC-IV) representing general and critical care populations.

Findings The proposed methodology showed its ability to derive meaningful clinical phenotypes of AF. Because of its probabilistic foundations, it can enhance the robustness of patient stratification. It also produced interpretable visualisation of complex high-dimensional data, enhancing understanding of the derived phenotypes and their key characteristics. Using our methodology, we identified and characterised clinical phenotypes of AF across diverse patient populations.

Interpretation Our methodology is robust to noise, can uncover hidden patterns and subgroups, and can elucidate more specific patient profiles, contributing to more robust patient stratification, which could facilitate the tailoring of prevention and treatment programs specific to each phenotype. It can also be applied to other datasets to derive clinically meaningful phenotypes of other conditions.

Jan, 22 2024 (v1) - Other (Open Access)

KoM Press Release - TARGET Project Takes Flight: A Paradigm Shift in Atrial Fibrillation and Stroke Management

Vivani, Laura; Christofidis, Veronica

Uploaded on Jan, 23 2024

January 22nd, 2023 – The Horizon Europe project TARGET - Health virtual twins for the personalised management of stroke related to atrial fibrillation, kicked off today with an exciting two-days meeting in Liverpool. TARGET’s ambition is to develop novel personalised, integrated, multi-scale computational models (virtual twins) and decision support tools for the AF-related stroke (AFRS) pathway, starting from the healthy state, pathophysiology and disease onset, progression, treatment, and recovery. In this sense, TARGET represents a milestone project to improve the care and rehabilitation of patients with AF and AFRS, introducing a paradigm shift in risk prediction, diagnosis, and management of the disease, and accelerating translational research into practice.